Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20074102 | 0.81 | KDM5B (0.46) | KDM5BBRD4CREBBPEP300KDM5A | |
| SCHEMBL20074091 | 0.81 | KDM5B (0.39) | KDM5BBRD4CREBBPEP300KDM5A | |
| SCHEMBL20074099 | 0.80 | KDM5B (0.50) | KDM5BKDM5AKDM5CKDM4C | |
| SCHEMBL20074272 | 0.78 | KDM5B (0.51) | KDM5BBRD4CREBBPKDM5APIK3CD | |
| SCHEMBL20074270 | 0.77 | KDM5B (0.51) | KDM5BKDM5AKDM5CKDM4C | |
| SCHEMBL20074321 | 0.72 | KDM5B (0.38) | KDM5BBRD4CREBBPEP300KDM5A | |
| SCHEMBL20074269 | 0.71 | PTGS1 (0.47) | KDM5B | |
| SCHEMBL20074104 | 0.71 | KDM5B (0.45) | KDM5BBRD4KDM5AAURKB | |
| SCHEMBL20074143 | 0.70 | KDM5B (0.41) | KDM5BKDM5AKDM5CKDM4C | |
| SCHEMBL21720979 | 0.70 | KDM5B (0.55) | KDM5BKDM5AKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525785-B1 | KDM5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-08-27 | — | — | EP | claimed |
| US-10975084-B2 | KDM5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200048258-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2018071283-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048258-A1 | KDM5 INHIBITORS | KDM5A, KDM5B, KDM5C | KDM5B 2/4885BRD4 72/4885CREBBP 1476/4885 |
| US-10975084-B2 | KDM5 inhibitors | KDM5A, KDM5B, KDM5C | KDM5B 2/4885BRD4 72/4885CREBBP 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.